BALAXI
OVERVALUEDBALAXI PHARMACEUTICALS LIMITED
Pharma · NSE
↓ 302.4% vs fair value
52W Low
₹15
+64.1% from low
52W High
₹64
-61.0% from high
Valuation Gauge
Current Price
₹25
Fair Value
₹6
Fair Value Analysis
₹6
Based on earnings growth potential for Pharma sector companies | Sector-cheap: P/E at 10th percentile vs sector peers. | CAUTION: ROCE declining (latest 11.2%) — returns on capital are falling; verify this isn't a value trap. | Growth capped at 4.6% (ROE 4.0%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable.
Growth Valuation
100% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Mixed Signals
Profitability
ROE of 4.0% is below the Pharma sector benchmark of 18%
Debt & Leverage
D/E ratio of 0.2x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 15.0x trades at a 64% discount to Pharma sector median (42x) — attractively valued
Cash Flow
Negative FCF of ₹-57 Cr — company is consuming more cash than it generates
Earnings Growth
5yr EPS CAGR of -19.3% — earnings are declining (sector avg growth: 15.3%)
Dividend
No dividend — typical for growth-stage companies
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
-42.6%
Free cash flow / market cap
Revenue Growth (YoY)
-1.0%
Year-on-year revenue change
Profit Growth (YoY)
-94.2%
Year-on-year PAT change
Operating Cash Flow
₹-35 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹1.7
P/E Ratio
15x
P/B Ratio
0.6x
ROE
4%
ROCE
12.4%
Debt / Equity
0.24x
Beta
0.75
Div Yield
—
FCF (Cr)
₹-57 Cr
Revenue (Cr)
₹293 Cr
EPS Growth 5Y
-19.3%
Mkt Cap (Cr)
₹143 Cr
52W High
₹63.9
52W Low
₹15.2
Book Value/Share
₹46.1
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹276 Cr | ₹21 Cr | 8.0% | ₹9 Cr | ₹1.72 |
| 2025-03-31 | ₹293 Cr | ₹32 Cr | 11.0% | ₹25 Cr | ₹4.54 |
| 2024-03-31 | ₹241 Cr | ₹45 Cr | 18.0% | ₹-2 Cr | ₹-0.44 |
| 2023-03-31 | ₹336 Cr | ₹57 Cr | 17.0% | ₹46 Cr | ₹9.03 |
| 2022-03-31 | ₹279 Cr | ₹51 Cr | 18.0% | ₹48 Cr | ₹9.53 |
| 2021-03-31 | ₹231 Cr | ₹43 Cr | 18.0% | ₹38 Cr | ₹7.63 |
| 2020-03-31 | ₹46 Cr | ₹8 Cr | 18.0% | ₹6 Cr | ₹1.22 |
| 2019-03-31 | ₹14 Cr | ₹2 Cr | 11.0% | ₹2 Cr | ₹1.30 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86.4 | ₹469.7 | +81.6% | 7.7 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹118.2 | ₹237.8 | +50.3% | 26.8 | 5.2% | FAIRLY_VALUED |
Bal Pharma Limited | ₹82.3 | ₹147.5 | +44.2% | 15.7 | 12.6% | FAIRLY_VALUED |
Lincoln Pharmaceuticals Limited | ₹732.1 | ₹1,131.6 | +35.3% | 14.7 | 13.1% | FAIRLY_VALUED |
Zydus Lifesciences | ₹1,038.6 | ₹1,502.2 | +30.9% | 20.6 | 19.9% | UNDERVALUED |
Lupin | ₹2,270.7 | ₹3,112 | +27.0% | 19.5 | 26.9% | UNDERVALUED |
Natco Pharma | ₹1,170 | ₹1,571.3 | +25.5% | 13.8 | 18.0% | UNDERVALUED |
Sudeep Pharma Limited | ₹675 | ₹739.2 | +8.7% | 43.7 | 21.4% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant